Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEM-DOAC: DOACs vs LMWH for VTE Prophylaxis in Hematologic Malignancies
NCT07270263Recruiting
- Sponsor
- Medical University of Gdańsk
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of apixaban and rivaroxaban in venous thromboembolism (VTE) (3 arms), sponsored by Medical University of Gdańsk. Primary endpoints: Incidence of Venous Thromboembolism at 6 months, Incidence of Major Bleeding at 6 months and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
apixabanrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07270263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07270263.